Shriram Properties Limited ipo details.
After Lodha Devlopers Another Real estate company ipo coming.
Shriram Properties files DRHP for ipo.
|Issue Type||Book Built Issue|
|Issue Price||₹0 to ₹0|
|Issue Size||₹0 per share|
|Face Value||No Update|
|Market Lot||0 Shares|
Key Dates of Ipo
|Ipo Open On||2021|
|Ipo Closes On||2021|
|Credit To Demat||2021|
Financials of the Company
|Total Revenue||420.11 Cr||353.31 Cr||574.69 Cr|
|Total Expenses||449.41 Cr||515.89 Cr||1051.18 Cr|
|Net Profit||349.26 Cr||(6.81 Cr)||(500.01 Cr)|
|Min||1 Lot||0 shares||₹0|
|Max||0 Lot||0 shares||₹0|
Company Contact Detail
|SHRIRAM PROPERTIES LIMITED|
Lakshmi Neela Rite Choice Chamber, New No. 9, Bazullah Road, T. Nagar,
Chennai 600 017, Tamil Nadu, India
Tel No.: +91 44 4001 4410
Email: [email protected]
|Karvy Fintech Private Limited|
Plot No. 31 & 32, Financial District
Nanakramguda, Serilingampally, Hyderabad
Rangareddi, 500 032 Telangana, India
Tel: +91 40 6716 2222
E-mail: [email protected]
Lead Manager of Ipo
|Edelweiss Financial Services|
Frequently Asked Questions
Q.1 what is the issue price of Shriram Properties ipo?
A.1 Currently, there are no update about the issue price of Shriram Properties ipo.
Q.2 what is the issue size of Shriram Properties ipo?
A.2 Issue size of Shriram Properties ipo is Rs.800 crore.
Q.3 What is the lot size of Shriram Properties ipo?
A.3 No update.
Q.4 what is the allotment date is Shriram Properties ipo?
A.4 No update
Q.5 what is the listing date of Shriram Properties ipo?
A.5 No update
Q.6 When will Shriram Properties ipo open?
A.6 No update.
Q.7 Who is the Registrar of Shriram Properties ipo?
A.7 Link Intime India is the Registrar ofShriram Properties ipo.
Q.8 who is the lead managers of the Shriram Properties ipo?
A.8 There are 3 Lead managers of this ipo.
* Axis Capital
* Edelweiss Financial Services
* JM Financials
* Nomura Financial Advisory and Securities
Hey, thank for reading this article.
Feel free to share your thoughts and questions in comment.
Don't forget to share it with your friends, family and colleagues.